WEKO3
インデックスリンク
アイテム
{"_buckets": {"deposit": "e9ec6319-8ef5-418c-803d-010750815d76"}, "_deposit": {"created_by": 3, "id": "14800", "owners": [3], "pid": {"revision_id": 0, "type": "depid", "value": "14800"}, "status": "published"}, "_oai": {"id": "oai:kanazawa-u.repo.nii.ac.jp:00014800", "sets": ["1135"]}, "author_link": ["22059", "22233", "26493", "26491", "640", "26492"], "item_4_biblio_info_8": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2005-06-01", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "6", "bibliographicPageEnd": "450", "bibliographicPageStart": "445", "bibliographicVolumeNumber": "31", "bibliographic_titles": [{"bibliographic_title": "医療薬学"}]}]}, "item_4_description_21": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "We examined the influence of basic drugs and protein variants on the binding disposition of ropivacaine to α_1-acid glycoprotein (AGP). On doing this, we found the values of the competitive inhibition constant (K_i) for dipyridamole, verapamil, lidocaine and disopyramide with respect to the binding of ropivacaine to commercial AGP (70mg/dL) to be 2.1, 5.2, 6.0 and 11.0μM, respectively. Also, there was a strong correlation between the f_u value and the AGP concentration when ropivacaine was added to plasma samples from ten healthy volunteers (r=0.861). Among the volunteers, eight showed F_1S variants and two showed F_1 variants without the S variant of AGP. There was no difference in the f_u value of ropivacaine between these two groups. However, when ropivacaine was added together with dipyridamole, the f_u values of ropivacaine in plasma from volunteers with F_1S variants were clearly higher than those from volunteers without the S variant. When ropivacaine was added together with disopyramide or lidocaine, however, there was no difference in f_u values between these variants. Our results indicate that variability in the effectiveness and/or adverse effects of ropivacaine are caused by changes in f_u as a consequence of changes in AGP concentration. They also suggest that in combination therapy, it is also important to consider the AGP variant-dependence of the inhibitory effect of concomitantly administered drugs", "subitem_description_type": "Abstract"}]}, "item_4_description_5": {"attribute_name": "提供者所属", "attribute_value_mlt": [{"subitem_description": "金沢大学大学院自然科学研究科分子作用学", "subitem_description_type": "Other"}, {"subitem_description": "金沢大学医学部附属病院薬剤部", "subitem_description_type": "Other"}, {"subitem_description": "金沢大学大学院医学系研究科", "subitem_description_type": "Other"}]}, "item_4_publisher_17": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "日本医療薬学会"}]}, "item_4_source_id_9": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "1346-342X", "subitem_source_identifier_type": "ISSN"}]}, "item_4_version_type_25": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_970fb48d4fbd8a85", "subitem_version_type": "VoR"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "石崎, 純子"}], "nameIdentifiers": [{"nameIdentifier": "640", "nameIdentifierScheme": "WEKO"}, {"nameIdentifier": "60401890", "nameIdentifierScheme": "金沢大学研究者情報", "nameIdentifierURI": "http://ridb.kanazawa-u.ac.jp/public/detail.php?kaken=60401890"}, {"nameIdentifier": "60401890", "nameIdentifierScheme": "研究者番号", "nameIdentifierURI": "https://nrid.nii.ac.jp/nrid/1000060401890"}]}, {"creatorNames": [{"creatorName": "下村, 祥子"}], "nameIdentifiers": [{"nameIdentifier": "26491", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "福和, 千恵"}], "nameIdentifiers": [{"nameIdentifier": "26492", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "嶋田, 努"}], "nameIdentifiers": [{"nameIdentifier": "26493", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "横川, 弘一"}], "nameIdentifiers": [{"nameIdentifier": "22233", "nameIdentifierScheme": "WEKO"}, {"nameIdentifier": "50283122", "nameIdentifierScheme": "研究者番号", "nameIdentifierURI": "https://nrid.nii.ac.jp/nrid/1000050283122"}]}, {"creatorNames": [{"creatorName": "宮本, 謙一"}], "nameIdentifiers": [{"nameIdentifier": "22059", "nameIdentifierScheme": "WEKO"}, {"nameIdentifier": "30100514", "nameIdentifierScheme": "研究者番号", "nameIdentifierURI": "https://nrid.nii.ac.jp/nrid/1000030100514"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2017-10-03"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "PR-ISHIZAKI-J-445.pdf", "filesize": [{"value": "981.1 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 981100.0, "url": {"label": "PR-ISHIZAKI-J-445.pdf", "url": "https://kanazawa-u.repo.nii.ac.jp/record/14800/files/PR-ISHIZAKI-J-445.pdf"}, "version_id": "b7d27ab1-1341-4ae2-826b-6715678ef746"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "ropivacaine α_1-acid glycoprotein protein binding drug interaction", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "jpn"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "局所麻酔薬ropivacaineのα_1-酸性糖タンパク結合動態と薬物間相互作用の検討", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "局所麻酔薬ropivacaineのα_1-酸性糖タンパク結合動態と薬物間相互作用の検討"}, {"subitem_title": "Binding Disposition of Local Anesthetic Ropivacaine to α_1-acid Glycoprotein and Interactions with Co-administered Drugs", "subitem_title_language": "en"}]}, "item_type_id": "4", "owner": "3", "path": ["1135"], "permalink_uri": "http://hdl.handle.net/2297/6253", "pubdate": {"attribute_name": "公開日", "attribute_value": "2017-10-03"}, "publish_date": "2017-10-03", "publish_status": "0", "recid": "14800", "relation": {}, "relation_version_is_last": true, "title": ["局所麻酔薬ropivacaineのα_1-酸性糖タンパク結合動態と薬物間相互作用の検討"], "weko_shared_id": -1}
局所麻酔薬ropivacaineのα_1-酸性糖タンパク結合動態と薬物間相互作用の検討
http://hdl.handle.net/2297/6253
http://hdl.handle.net/2297/6253bbf7ccf5-b7b4-4106-8bda-a7c68c8e24ca
名前 / ファイル | ライセンス | アクション |
---|---|---|
PR-ISHIZAKI-J-445.pdf (981.1 kB)
|
|
Item type | 学術雑誌論文 / Journal Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2017-10-03 | |||||
タイトル | ||||||
タイトル | 局所麻酔薬ropivacaineのα_1-酸性糖タンパク結合動態と薬物間相互作用の検討 | |||||
タイトル | ||||||
言語 | en | |||||
タイトル | Binding Disposition of Local Anesthetic Ropivacaine to α_1-acid Glycoprotein and Interactions with Co-administered Drugs | |||||
言語 | ||||||
言語 | jpn | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
資源タイプ | journal article | |||||
著者 |
石崎, 純子
× 石崎, 純子× 下村, 祥子× 福和, 千恵× 嶋田, 努× 横川, 弘一× 宮本, 謙一 |
|||||
提供者所属 | ||||||
内容記述タイプ | Other | |||||
内容記述 | 金沢大学大学院自然科学研究科分子作用学 | |||||
提供者所属 | ||||||
内容記述タイプ | Other | |||||
内容記述 | 金沢大学医学部附属病院薬剤部 | |||||
提供者所属 | ||||||
内容記述タイプ | Other | |||||
内容記述 | 金沢大学大学院医学系研究科 | |||||
書誌情報 |
医療薬学 巻 31, 号 6, p. 445-450, 発行日 2005-06-01 |
|||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 1346-342X | |||||
出版者 | ||||||
出版者 | 日本医療薬学会 | |||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | We examined the influence of basic drugs and protein variants on the binding disposition of ropivacaine to α_1-acid glycoprotein (AGP). On doing this, we found the values of the competitive inhibition constant (K_i) for dipyridamole, verapamil, lidocaine and disopyramide with respect to the binding of ropivacaine to commercial AGP (70mg/dL) to be 2.1, 5.2, 6.0 and 11.0μM, respectively. Also, there was a strong correlation between the f_u value and the AGP concentration when ropivacaine was added to plasma samples from ten healthy volunteers (r=0.861). Among the volunteers, eight showed F_1S variants and two showed F_1 variants without the S variant of AGP. There was no difference in the f_u value of ropivacaine between these two groups. However, when ropivacaine was added together with dipyridamole, the f_u values of ropivacaine in plasma from volunteers with F_1S variants were clearly higher than those from volunteers without the S variant. When ropivacaine was added together with disopyramide or lidocaine, however, there was no difference in f_u values between these variants. Our results indicate that variability in the effectiveness and/or adverse effects of ropivacaine are caused by changes in f_u as a consequence of changes in AGP concentration. They also suggest that in combination therapy, it is also important to consider the AGP variant-dependence of the inhibitory effect of concomitantly administered drugs | |||||
著者版フラグ | ||||||
出版タイプ | VoR | |||||
出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 |